Innovation and Equity in Breast Cancer. HER2-Low: A Real Opportunity or a Mirage for Low- and Middle-Income Countries?

Abstract

Equity in breast cancer treatment in the era of innovation is one of the greatest public?health challenges,
particularly in low- and middle-income countries (LMICs). While the past two decades have brought notable
advances in diagnosis, targeted therapies, and precision medicine, gaps between population groups, geographic
regions, and socioeconomic strata remain profound [1]. Likewise, multiple recent studies indicate that these
inequities appear as differences in stage at diagnosis, lower access to mammography, and greater difficulty
receiving standard treatments ultimately translating into lower survival rates.